Inclusion Criteria:

- Histologically confirmed AJCC/UICC high-risk stage II or stage III colon cancer .
High-risk stage III patients (T4, N+, M0, or any T, N2, M0) may also be further
randomized in the BEV study (plus or minus BEV)

- Stage II patients have to be considered at high-risk if they fulfill >1 of the
following criteria:

- T4 tumours,

- grade >3,

- clinical presentation with bowel obstruction or perforation,

- histological signs of vascular or lymphatic or perineural invasion,

- <12 nodes examined

- Age 18 to 75 years

- Curative surgery no less than 3 ( 4 in the BEV study) and no more than 8 weeks prior
to randomization

- ECOG performance Status (ECOG-PS) <1

- Signed written informed consent obtained prior to any study specific procedures

Exclusion Criteria:

- Macroscopic or microscopic evidence of residual tumor (R1 or R2 resections).

- Previous anti-angiogenic treatment for any malignancy; cytotoxic chemotherapy,
radiotherapy or immunotherapy for colon cancer

- Other malignancies within the last 5 years (other than curatively treated basal cell
carcinoma of the skin and/or in situ carcinoma of the cervix)

- Lactating women

- Fertile women (<2 years after last menstruation) and men of childbearing potential
not willing to use effective means of contraception

- History of clinically relevant psychiatric disability , precluding informed consent

- Clinically relevant cardiovascular disease

- History or presence of other diseases

- Evidence of bleeding diathesis or coagulopathy

- Current or recent (within 10 days prior to study treatment start) use of full-dose
oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes

- Chronic, daily treatment with high-dose aspirin (>325 mg/day) or clopidogrel (>75
mg/day)

- Current or recent (within the 28 days prior to randomization) treatment with another
investigational drug or participation in another investigational study